UNIGE document Scientific Article
previous document  unige:116659  next document
add to browser collection
Title

Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study

Authors show hidden authors show all authors [1 - 13]
Published in Journal of Clinical Psychopharmacology. 2018, vol. 38, no. 6, p. 590-597
Abstract BACKGROUND: Ketamine has been documented for its rapid antidepressant effects. However, optimal dose and delivery route have not yet been thoroughly investigated. The objectives of this study were to document the safety and test the antidepressant and antisuicidal effects of a single rapid 1-minute injection of ketamine 0.5 mg/kg in treatment-resistant depression (TRD). METHODS: Ten patients with TRD were included in an open, noncontrolled 4-week study and received a rapid intravenous dose of ketamine 0.5 mg/kg. Main outcome measure was the Montgomery-Asberg Depression Rating Scale and suicidality was assessed using the Scale for Suicide Ideation. RESULTS: Rapid injection of ketamine elicited transient increase of blood pressure and altered states of consciousness in all patients and mild psychotomimetic effects in 4 patients, which all resolved without any intervention. Decrease of depression severity was observed from 40-minute postinjection until day 15. Eight patients became responders within 1 day and all were nonresponders after 4 weeks. The decrease of suicidal ideation was significant until day 7. Analysis indicated that higher severity of depression and anxiety at baseline predicted a larger Montgomery-Asberg Depression Rating Scale decrease after 4 weeks. CONCLUSIONS: This study suggests that in well-controlled medical settings with adequate monitoring, a single rapid 1-minute injection of ketamine 0.5 mg/kg can be well tolerated and is efficacious in rapidly reducing depression symptoms and suicidal thoughts in outpatients with TRD. These findings are relevant to the practice of general clinical psychiatry and emergency departments were ketamine can have a place in acute management of TRD. Larger studies are necessary to confirm these results.
Identifiers
PMID: 30346333
Full text
Article (Published version) (260 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Article (Accepted version) (655 Kb) - public document Free access
Other version: http://Insights.ovid.com/crossref?an=00004714-900000000-98638
Structures
Research groups Neuroimagerie du Sommeil et de la Cognition (832)
Groupe Dayer Alexandre (Formation du circuit cortical) (875)
Traitement et neurobiologie de la dépression (916)
Thérapeutiques des Troubles de l'Humeur et Anxieux (689)
Anesthésie et neurosciences (883)
NCCR Synapsy
Project FNS: 135554
Citation
(ISO format)
VIDAL, Sonia et al. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study. In: Journal of Clinical Psychopharmacology, 2018, vol. 38, n° 6, p. 590-597. doi: 10.1097/JCP.0000000000000960 https://archive-ouverte.unige.ch/unige:116659

239 hits

155 downloads

Update

Deposited on : 2019-04-25

Export document
Format :
Citation style :